These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35139799)

  • 1. Privileged Scaffolds Targeting Bromodomain-containing Protein 4.
    Wang R; Wang YA; Xu YG; Shi L
    Curr Top Med Chem; 2022; 22(7):600-627. PubMed ID: 35139799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A patent review of BRD4 inhibitors (2013-2019).
    Lu T; Lu W; Luo C
    Expert Opin Ther Pat; 2020 Jan; 30(1):57-81. PubMed ID: 31815566
    [No Abstract]   [Full Text] [Related]  

  • 3. Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics.
    Cai M; Dong J; Li H; Qin JJ
    Curr Med Chem; 2022; 29(25):4391-4409. PubMed ID: 35152859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.
    Liang D; Yu Y; Ma Z
    Eur J Med Chem; 2020 Aug; 200():112426. PubMed ID: 32502863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Hydroxyisoindolin-1-one derivates: Synthesis by palladium-catalyzed CH activation as BRD4 inhibitors against human acute myeloid leukemia (AML) cells.
    Chen P; Yang Y; Yang L; Tian J; Zhang F; Zhou J; Zhang H
    Bioorg Chem; 2019 May; 86():119-125. PubMed ID: 30690335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural variation of protein-ligand complexes of the first bromodomain of BRD4.
    Guest EE; Pickett SD; Hirst JD
    Org Biomol Chem; 2021 Jun; 19(25):5632-5641. PubMed ID: 34105560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research Advances in the Mechanisms of BRD4 and Its Inhibitors in Hematologic Malignancies--Review].
    Gao RL; Zeng CW; Li YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1365-1368. PubMed ID: 34362532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Structure-based Design Approach for Generating High Affinity BRD4 D1-Selective Chemical Probes.
    Cui H; Divakaran A; Hoell ZJ; Ellingson MO; Scholtz CR; Zahid H; Johnson JA; Griffith EC; Gee CT; Lee AL; Khanal S; Shi K; Aihara H; Shah VH; Lee RE; Harki DA; Pomerantz WCK
    J Med Chem; 2022 Feb; 65(3):2342-2360. PubMed ID: 35007061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel inhibitors of bromodomain and extra-terminal domain trigger cell death in breast cancer cell lines.
    Rahnasto-Rilla M; Puumalainen T; Karttunen V; Adla SK; Lahtela-Kakkonen M
    Bioorg Med Chem; 2024 Oct; 112():117884. PubMed ID: 39226716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 8-Methyl-pyrrolo[1,2-
    Li Z; Xiao S; Yang Y; Chen C; Lu T; Chen Z; Jiang H; Chen S; Luo C; Zhou B
    J Med Chem; 2020 Apr; 63(8):3956-3975. PubMed ID: 32208600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Dynamic Simulations of Bromodomain and Extra-Terminal Protein 4 Bonded to Potent Inhibitors.
    Chen S; He Y; Geng Y; Wang Z; Han L; Han W
    Molecules; 2021 Dec; 27(1):. PubMed ID: 35011350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic potential of BRD4 in cardiovascular disease.
    Lin S; Du L
    Hypertens Res; 2020 Oct; 43(10):1006-1014. PubMed ID: 32409773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomistic insights into the selective therapeutic activity of 6-(2,4-difluorophenoxy)-5-((ethylmethyl)pyridine-3-yl)-8-methylpyrrolo[1,2-a]pyrazin-1(2H)-one towards bromodomain-containing proteins.
    Akawa OB; Soremekun OS; Olotu FA; Soliman MES
    Comput Biol Chem; 2021 Dec; 95():107592. PubMed ID: 34710811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research progress of BRD4 in head and neck squamous cell carcinoma: Therapeutic application of novel strategies and mechanisms.
    Tang J; Chen H; Fan H; Chen T; Pu C; Guo Y
    Bioorg Med Chem; 2024 Nov; 113():117929. PubMed ID: 39317007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.
    Wang W; Tang YA; Xiao Q; Lee WC; Cheng B; Niu Z; Oguz G; Feng M; Lee PL; Li B; Yang ZH; Chen YF; Lan P; Wu XJ; Yu Q
    Nat Commun; 2021 Jul; 12(1):4441. PubMed ID: 34290255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.